A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 07 08 2018
accepted: 11 04 2019
entrez: 26 4 2019
pubmed: 26 4 2019
medline: 9 1 2020
Statut: epublish

Résumé

The Tec kinases ITK (interleukin-2-inducible T-cell kinase) and RLK (resting lymphocyte kinase) are critical components of the proximal TCR/CD3 signal transduction machinery, and data in mice suggest that ITK negatively modulates regulatory T cell (TREG) differentiation. However, whether Tec kinases modulate TREG development and/or function in human T cells remains unknown. Using a novel self-delivery siRNA platform (sdRNA), we found that ITK knockdown in human primary naïve peripheral blood CD4 T cells increased Foxp3+ expression under both TREG and T helper priming conditions. TREG differentiated under ITK knockdown conditions exhibited enhanced expression of the co-inhibitory receptor PD-1 and were suppressive in a T cell proliferation assay. ITK knockdown decreased IL-17A production in T cells primed under Th17 conditions and promoted Th1 differentiation. Lastly, a dual ITK/RLK Tec kinase inhibitor did not induce Foxp3 in CD4 T cells, but conversely abrogated Foxp3 expression induced by ITK knockdown. Our data suggest that targeting ITK in human T cells may be an effective approach to boost TREG in the context of autoimmune diseases, but concomitant inhibition of other Tec family kinases may negate this effect.

Identifiants

pubmed: 31022269
doi: 10.1371/journal.pone.0215963
pii: PONE-D-18-23276
pmc: PMC6483201
doi:

Substances chimiques

Forkhead Transcription Factors 0
Foxp3 protein, mouse 0
Programmed Cell Death 1 Receptor 0
Protein Kinase Inhibitors 0
Protein-Tyrosine Kinases EC 2.7.10.1
emt protein-tyrosine kinase EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215963

Déclaration de conflit d'intérêts

Takeda Pharmaceuticals USA. The funder provided support in the form of salaries for authors PM, RAE, JP, AD, JRF, and JRM. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Cell. 2011 Sep 2;146(5):772-84
pubmed: 21871655
Science. 1999 Apr 23;284(5414):638-41
pubmed: 10213685
J Exp Med. 2014 Mar 10;211(3):529-43
pubmed: 24534190
J Exp Med. 2010 Jul 5;207(7):1347-50
pubmed: 20603315
Biochem Soc Trans. 2001 Nov;29(Pt 6):863-7
pubmed: 11709089
Annu Rev Immunol. 2005;23:549-600
pubmed: 15771581
Oncogene. 1995 Jul 20;11(2):245-51
pubmed: 7542761
PLoS One. 2014 Sep 24;9(9):e107490
pubmed: 25250764
J Allergy Clin Immunol. 2006 Apr;117(4):780-6
pubmed: 16630934
Sci Signal. 2014 Aug 05;7(337):ra74
pubmed: 25097034
Nat Immunol. 2001 Dec;2(12):1183-8
pubmed: 11702066
Mol Cell Biol. 1999 Feb;19(2):1498-507
pubmed: 9891083
J Immunol. 2014 Sep 1;193(5):2267-72
pubmed: 25063868
Curr Biol. 2003 Sep 16;13(18):1619-24
pubmed: 13678593
J Neurosci. 2015 Jan 7;35(1):221-33
pubmed: 25568116
J Biol Chem. 2000 Feb 11;275(6):3835-40
pubmed: 10660534
J Immunol. 2008 Nov 1;181(9):6125-31
pubmed: 18941202
J Allergy Clin Immunol. 2013 Oct;132(4):811-20.e1-5
pubmed: 23768572
J Biol Chem. 2015 Mar 6;290(10):5960-78
pubmed: 25593320
Immunity. 2009 Oct 16;31(4):587-97
pubmed: 19818650
Sci Signal. 2015 Dec 01;8(405):ra122
pubmed: 26628680
Immunity. 1999 Oct;11(4):399-409
pubmed: 10549622
Eur J Immunol. 2015 Aug;45(8):2276-85
pubmed: 25989458

Auteurs

Polina Mamontov (P)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

Ryan A Eberwine (RA)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

Jackie Perrigoue (J)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

Anuk Das (A)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

Joshua R Friedman (JR)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

J Rodrigo Mora (JR)

Janssen Research & Development, Spring House, Pennsylvania, United States America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH